secwatch.observer — SEC 8-K summary
======================================

Issuer:     Microbot Medical Inc. (MBOT)
CIK:        0000883975
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001493152-23-042204
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Microbot Medical appoints Dr. Juan Diaz-Cartelle as CMO effective Dec 1, 2023
-----------------------------------------------------------------------------

- Dr. Diaz-Cartelle was previously Senior Medical Director at Boston Scientific (14 yrs) and Executive Medical Director at Haemonetics.
- Base salary $350,000, target bonus up to 30% of salary, and 25,000 stock options vesting over three years.
- He will lead U.S. clinical trials for the LIBERTY Endovascular Robotic Surgical System and FDA regulatory process.
- Succeeds Dr. Eyal Morag; company shifts focus from R&D in Israel to U.S.-based clinical and commercial activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/883975/000149315223042204/0001493152-23-042204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/883975/000149315223042204/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-042204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer